Five Stocks

$FIVE2GROW Q3 Portfolio Rebalance Update I manage this portfolio with a strict 5-stock limit and reevaluate it quarterly. After reviewing the current setup, I’m keeping the same five names for Q3 but changing the allocation. The main adjustment: MRVL is being reduced from the largest position to a smaller high-upside satellite position. I still like the long-term AI/data-center story, but I don’t think it should be the largest holding in a concentrated 5-stock portfolio given the relative risk, customer concentration, and execution dependency. New Q3 target allocation: AVGO: 23% NVDA: 22% AMZN: 22% VRTX: 18% MRVL: 15% The logic is simple: I want the largest weights in the highest-quality, most durable AI infrastructure and cloud compounders. AVGO, NVDA, and AMZN become the core of the portfolio. VRTX remains the non-tech diversifier with strong cash flow and pipeline optionality. MRVL stays in the portfolio, but at a more appropriate size for its risk/reward profile. This keeps the portfolio aggressive and AI-forward, but reduces the risk of having the most speculative name as the biggest position. As always, this is my portfolio decision based on my own risk tolerance and quarterly review process — not financial advice.

Q2 2026 rebalance: I tightened the portfolio around the strongest near-term AI and catalyst-driven names. I exited BA and DG, added NVDA and AVGO, kept AMZN, VRTX, and MRVL, and trimmed MRVL to reduce beta. New weights: AMZN 24% | NVDA 22% | AVGO 20% | VRTX 20% | MRVL 14%. Why the change: I wanted higher-probability upside over the next 3 months. Boeing still has too much execution and margin risk, and Dollar General looks solid but less likely to outperform in a growth-led market. The new mix leans harder into AI infrastructure demand while keeping Vertex as a differentiated healthcare catalyst. Current thesis: This portfolio is now concentrated in companies with strong near-term earnings, guidance, and product or regulatory catalysts. I’ll be watching AI capex commentary closely, plus upcoming earnings and Vertex’s regulatory milestones, and I’ll reassess again next quarter.

Portfolio refresh (5 stocks, Q1 2026): Rotated into a barbell of AI growth + operational turnarounds for near-term upside with controlled risk. New mix and weights: AMZN 26% (AWS + ads reaccel), MRVL 22% (AI infrastructure leverage), VRTX 20% (profitable biotech + new launches), BA 17% (delivery ramp/FCF inflection), DG 15% (turnaround + tax-refund seasonality). I’ll rebalance quarterly (or on ±5% drift) and trim the highest-beta name first if AI demand or execution signals weaken. Objective: maximize 3-month upside while diversifying drivers beyond mega-cap tech.